Biopharma | 04 December 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The partnership combines Croda’s deep expertise in smart science and global market reach with Amino’s advanced capabilities in precision manufacturing of amino acids
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Extended lab space for product development, customer demos, and training
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Subscribe To Our Newsletter & Stay Updated
